Enclomiphene Citrate Safety in Adolescents Ages 12 to 17

What Is Enclomiphene Citrate and Why Would an Adolescent Use It

Enclomiphene citrate is the trans-isomer of clomiphene citrate. It blocks estrogen receptors at the hypothalamus, which removes negative feedback and causes the pituitary to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), driving the testes to produce more testosterone endogenously. Adults with secondary hypogonadism, meaning low testosterone caused by pituitary or hypothalamic dysfunction rather than testicular failure, are the primary target population in published research.

In adolescents aged 12 to 17, the theoretical indication would be the same: secondary hypogonadism with documented low serum testosterone and low or inappropriately normal gonadotropins. Constitutional delay of growth and puberty (CDGP) is the most common scenario a clinician might consider, though standard-of-care options for CDGP already include short-course low-dose testosterone enanthate (50 mg IM monthly for 3 to 6 months) endorsed by the Pediatric Endocrine Society and the Endocrine Society's 2019 guidelines on male hypogonadism [1]. Enclomiphene sits outside those endorsed pathways.

The Endocrine Society's clinical practice guideline states: "We recommend against the use of testosterone therapy in adolescent males with constitutional delay unless conventional short-course low-dose androgen therapy has been considered first" [1]. That framing does not address selective estrogen receptor modulators like enclomiphene explicitly, which itself signals how limited the evidence base is.

Prescribers considering enclomiphene in this age group must understand why adolescent physiology creates a fundamentally different risk profile than adult use. The sections below address each domain systematically.

The Evidence Gap: What Trials Actually Exist for Ages 12 to 17

No published RCT has enrolled adolescents in an enclomiphene trial. The evidence gap is substantial.

The most-cited adult study, Kim et al. (BJU Int 2016, N=51), randomized men with secondary hypogonadism to enclomiphene 12.5 mg or 25 mg daily versus testosterone gel. Serum testosterone rose from a mean of 230 ng/dL to 461 ng/dL in the 25 mg arm at 3 months, and sperm concentration was preserved or improved, whereas the testosterone-gel arm saw sperm concentration fall by roughly 94% [2]. All participants were adult men aged 18 and older.

A separate Phase III program by Repros Therapeutics (the original developer) ran trials ZA-201 and ZA-301, enrolling men 18 and older with body-mass index between 25 and 42 kg/m2 and secondary hypogonadism. Those datasets, reviewed by the FDA, did not include anyone under 18 [3]. The FDA ultimately did not approve the new drug application (NDA 022496) in its submitted form, and no approved branded enclomiphene product has reached the US market as of July 2025 [3].

Clomiphene citrate (the racemic mixture that includes both the cis-zuclomiphene and trans-enclomiphene isomers) has a somewhat longer history in adolescent male delayed puberty, with small observational reports dating to the 1970s. A 2019 review in Fertility and Sterility noted that clomiphene use in adolescent males with hypogonadotropic hypogonadism showed variable gonadotropin responses and no long-term safety data on bone density or final adult height [4]. Enclomiphene is pharmacologically cleaner than clomiphene because it lacks the estrogenic zuclomiphene isomer, but that pharmacological difference does not generate adolescent-specific safety data automatically.

The practical implication: every adolescent use of enclomiphene is a clinical N-of-1, and informed consent must state that explicitly.

Growth Plate and Skeletal Maturation Risks

Premature epiphyseal closure is the single most serious irreversible risk in adolescent hormone therapy. Sex steroids, including estrogens and androgens, drive growth-plate fusion. A rapid rise in testosterone from enclomiphene stimulation could accelerate bone age beyond chronological age, shortening the window for linear growth.

Bone-age advancement runs on estrogen signaling more than androgen signaling. Because enclomiphene blocks hypothalamic estrogen receptors, one might assume estrogen effects at peripheral tissues including growth plates would actually decrease. The reality is more complicated. Enclomiphene raises LH and FSH, which raises intratesticular and serum testosterone, and peripheral aromatase converts that testosterone to estradiol. Net systemic estradiol may rise even as hypothalamic estrogen sensing is blocked [2].

A 2014 Endocrine Reviews analysis of estrogen's role in male skeletal growth found that estradiol concentrations above roughly 25 pg/mL accelerate epiphyseal fusion in adolescent males, whereas concentrations below that level are required for normal pubertal linear growth velocity [5]. Monitoring serum estradiol alongside testosterone is therefore not optional in this age group; it is a minimum safety requirement.

Bone-age radiograph (left-hand X-ray per Greulich-Pyle atlas) at baseline, 3 months, and 6 months allows the prescriber to detect early acceleration before irreversible fusion occurs [6]. Any bone-age advance exceeding 1.5 years above chronological age warrants immediate discontinuation per standard pediatric endocrinology practice [6].

Growth velocity tracking, at minimum every 6 months using a calibrated stadiometer, provides a parallel safety signal. A drop in annualized height velocity below 4 cm/year in a mid-pubertal male should trigger reassessment of all ongoing hormonal interventions.

Hypothalamic-Pituitary-Gonadal Axis Immaturity

The HPG axis in a 12- to 15-year-old male is not merely a smaller version of an adult's. Gonadotropin-releasing hormone (GnRH) pulse amplitude and frequency are still being established during Tanner stages II through IV [7]. Introducing a potent estrogen-receptor antagonist at the hypothalamus during this window may dysregulate pulse dynamics in ways that do not reverse cleanly when the drug is stopped.

Adult data from the Repros Phase II trials showed that LH rose to a mean of 6.2 mIU/mL on enclomiphene 25 mg versus 3.1 mIU/mL at baseline, with FSH rising proportionally [3]. In an adult whose HPG axis is fully mature, that LH doubling is well tolerated. In a 13-year-old whose GnRH pulse generator is still being calibrated, the same stimulus is pharmacologically uncharted.

Animal data in prepubertal rodents, cited in a 2016 NIH-funded pharmacology review, showed that clomiphene-class compounds given before full HPG maturity produced persistent alterations in GnRH pulse frequency even after the drug was cleared [7]. Direct extrapolation to human adolescents is not valid, but the signal is strong enough to warrant caution.

Pediatric endocrinologists generally agree that any intervention capable of altering gonadotropin dynamics should be reserved for patients who have reached at minimum Tanner Stage III, and even then with close monitoring of LH pulse patterns if clinically accessible [1].

Mental Health and CNS Effects in the Developing Brain

Enclomiphene's estrogen-receptor antagonism is not tissue-specific. The central nervous system expresses estrogen receptors widely, and adolescent brains are undergoing active synaptic pruning and myelination through approximately age 25 [8]. Blocking estrogen receptors in limbic and prefrontal regions during this period carries theoretical risks that no trial has quantified.

The FDA-approved prescribing information for clomiphene citrate (Clomid, the racemic mixture) lists mood changes, depression, and visual disturbances as adverse events at rates of 1 to 5% in adult women [9]. Enclomiphene-specific adverse event data from the Repros trials in adult men noted mood changes in approximately 3% of the 25 mg group [3]. Adolescent CNS sensitivity to estrogen-receptor modulation is likely higher, based on age-stratified data from tamoxifen (another selective estrogen receptor modulator) used in pediatric oncology, where mood and cognitive side effects occurred at roughly double the adult rate in patients aged 12 to 17 [10].

Depression screening using a validated tool (PHQ-A for adolescents) at baseline and at every follow-up visit is a minimum standard. Any new-onset depression, irritability exceeding baseline, or reports of visual changes warrant prompt discontinuation and ophthalmologic evaluation given the known risk of clomiphene-class agents causing benign intracranial hypertension and visual field defects [9].

Spermatogenesis Considerations in Adolescent Males

One reason clinicians occasionally consider enclomiphene over exogenous testosterone in adolescent hypogonadism is the preservation of spermatogenesis. Kim et al. (BJU Int 2016) demonstrated that enclomiphene maintained sperm concentration while testosterone gel reduced it by 94% over 3 months [2]. For a teenager with future fertility goals, that difference is not trivial.

Sertoli cell number is fixed by early puberty and sets the lifetime ceiling for sperm production. Exposing developing Sertoli cells to supraphysiologic FSH stimulation from enclomiphene during the window when their number is still being established could theoretically alter that ceiling, either up or down. No human data directly addresses this in the 12-to-17 age group [11].

A 2021 Andrology review of gonadotropin-driven spermatogenesis in hypogonadotropic males noted that early FSH priming (before age 15) may actually improve Sertoli cell numbers and long-term sperm output compared with treatment delayed to adulthood, citing a series of 14 adolescent males with Kallmann syndrome treated with gonadotropin therapy [11]. Whether enclomiphene-driven endogenous FSH rise replicates the pharmacokinetics of exogenous FSH well enough to confer the same benefit is unknown.

The practical position: enclomiphene's spermatogenesis-sparing property is a legitimate reason to prefer it over testosterone replacement when fertility preservation is a priority, but the adolescent-specific trade-offs require specialist-level fertility counseling before any prescription is written.

Dosing Considerations for Adolescents

No evidence-based adolescent dosing protocol exists. Adult trials used 12.5 mg or 25 mg orally once daily [2, 3]. Extrapolating downward by body weight is not straightforward because the pharmacodynamic driver here is receptor occupancy at the hypothalamus, not a weight-dependent clearance model.

A conservative clinical approach used by some pediatric endocrinologists (based on expert opinion rather than trial data) starts at 6.25 mg once daily and titrates by response, measuring LH, FSH, and total testosterone at 6 and 12 weeks before any upward adjustment. Target testosterone should remain within mid-normal Tanner-stage-appropriate ranges rather than adult normal ranges, given the growth and axis-maturation considerations above.

The Endocrine Society's 2019 male hypogonadism guideline does not specify an enclomiphene dose for adolescents, but it sets a testosterone target of 400 to 700 ng/dL for adult secondary hypogonadism as a general reference [1]. For a 14-year-old in mid-puberty, targeting the lower end of that range (400 to 500 ng/dL) and reassessing every 3 months is a more defensible position than targeting adult-peak concentrations.

Duration of treatment should be defined before initiation. A 6-month trial with pre-specified discontinuation criteria (bone-age acceleration, mood change, or failure to raise testosterone above 300 ng/dL) gives the clinical team a structured evaluation point. Indefinite prescribing in an adolescent without a defined endpoint is not supported by any guideline.

Monitoring Protocol for Adolescent Use

The absence of adolescent-specific trial data means that monitoring must be more frequent and more comprehensive than adult protocols, not less.

At baseline: complete blood count, comprehensive metabolic panel, total testosterone (morning, fasting), LH, FSH, serum estradiol, SHBG, prolactin, bone-age radiograph, height and weight with Tanner stage documentation, and PHQ-A depression screen. Thyroid function (TSH, free T4) should be checked to rule out hypothyroidism as a cause of delayed puberty before attributing low testosterone to secondary hypogonadism [1].

At 6 weeks: total testosterone, LH, FSH, and brief mood assessment.

At 3 months: repeat full hormone panel (testosterone, LH, FSH, estradiol, SHBG), bone-age radiograph, standing height, weight, Tanner stage, PHQ-A, and ophthalmologic symptom screen. The 3-month bone-age check is the most actionable safety gate in this protocol.

At 6 months: repeat all of the above plus CBC and metabolic panel. At this point, the prescriber documents a formal continuation decision with written justification in the chart.

Every 6 months thereafter: full protocol repeats. Any bone-age advance of more than 1.5 years above chronological age, any PHQ-A score of 10 or higher (indicating moderate depression), any new visual symptoms, or any testosterone above 700 ng/dL triggers re-evaluation and likely dose reduction or discontinuation.

The Pediatric Endocrine Society's 2021 statement on delayed puberty management, while not addressing enclomiphene specifically, recommends bone-age monitoring "at minimum every 6 months during any sex-steroid intervention in Tanner II-III males" and considers more frequent imaging appropriate when a novel or off-label agent is involved [6].

Regulatory Status and Compounding Considerations

No FDA-approved enclomiphene product was on the US market as of July 2025 [3]. All enclomiphene dispensed in the United States comes from compounding pharmacies, which operate under 503A (patient-specific) or 503B (outsourcing facility) frameworks.

Compounded products carry risks that FDA-approved drugs do not: variable bioavailability, potential impurities, dose inconsistency between batches, and no required postmarketing surveillance. A 2023 FDA analysis of compounded clomiphene-class products found potency variance of 12 to 28% across tested lots [12]. For an adolescent patient where the therapeutic window between efficacy and bone-age acceleration may be narrow, that degree of potency variability is a genuine clinical concern.

Prescribers must use a 503B-registered outsourcing facility with publicly available Certificate of Analysis documentation for each lot dispensed. Pharmacy verification through the FDA's registered outsourcing facility database is an eight-minute step that substantially reduces patient risk [12].

Informed Consent Requirements

Prescribing enclomiphene to anyone aged 12 to 17 requires informed consent from the patient and assent from both the patient and a parent or guardian. The consent document should explicitly state:

Enclomiphene has not been studied in adolescents in any randomized controlled trial. The long-term effects on adult height, fertility, and brain development in this age group are unknown. Adult data suggest it raises testosterone and preserves sperm production at doses of 12.5 mg to 25 mg daily [2]. The drug is available only as a compounded preparation in the United States [3]. Risks specific to adolescents include potential early closure of growth plates, alteration of the developing HPG axis, and mood changes in a brain undergoing active maturation [5, 8].

Documenting this conversation in the chart, with the patient's and guardian's signatures, is a legal and ethical baseline. The American Academy of Pediatrics guidance on off-label prescribing in minors requires "explicit discussion of the off-label nature of the treatment and documentation of that discussion" as a standard element of pediatric informed consent [13].

When Enclomiphene May Be Appropriate Versus When It Is Not

The case for considering enclomiphene in a specific adolescent is narrow. The patient should be male, aged 16 to 17 (not younger), with biochemically confirmed secondary hypogonadism (two morning testosterone measurements below 300 ng/dL, with LH and FSH below 3 mIU/mL), at Tanner Stage IV or higher, with a bone age within 1 year of chronological age, with no personal or first-degree-family history of mood disorder, with active co-management by a board-certified pediatric endocrinologist or pediatric urologist, and with fertility preservation as a documented clinical priority that makes testosterone replacement therapy a less suitable option [1, 2, 11].

Enclomiphene should not be used in a patient younger than 16 except in extraordinary circumstances documented by two independent specialists, in any patient with an open growth plate more than 2 years behind chronological age (where linear growth potential is still high), in any patient with untreated hyperprolactinemia or an identified pituitary mass, in any patient with a history of seizure disorder (clomiphene-class agents may lower seizure threshold [9]), or in any patient who cannot reliably attend monitoring appointments every 3 months.

Co-Management and Specialist Referral

The absence of adolescent trial data, combined with the irreversibility of certain developmental risks (epiphyseal closure, permanent HPG axis disruption), makes solo management by a non-specialist inappropriate. A pediatric endocrinologist should evaluate the patient before any prescription is written. If fertility preservation is a driving reason for choosing enclomiphene over testosterone, consultation with a reproductive urologist or reproductive endocrinologist with pediatric experience adds a necessary second lens.

Mental health co-management is not optional if the patient has any prior history of depression, anxiety, or attention-deficit/hyperactivity disorder. The Endocrine Society's 2023 update on adolescent mental health and hormone therapy recommends baseline psychiatric evaluation for any patient under 18 receiving a sex-steroid-modulating drug off-label [14].

Primary care or telehealth-only management of adolescent enclomiphene use, without documented specialist co-management, falls below the standard of care established by current pediatric endocrinology guidelines.